News coverage about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.1702543075671 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

A number of brokerages have weighed in on CRBP. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, August 9th. BidaskClub cut Corbus Pharmaceuticals Holdings from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, September 20th. Finally, ValuEngine cut Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $19.75.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) remained flat at $7.15 during mid-day trading on Friday. The company’s stock had a trading volume of 381,114 shares. The company’s market capitalization is $348.21 million. Corbus Pharmaceuticals Holdings has a 12-month low of $4.65 and a 12-month high of $10.78. The stock has a 50 day moving average of $6.51 and a 200 day moving average of $6.90.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.50 million. Equities research analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.66) earnings per share for the current fiscal year.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.